Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma HoldingsXERS +3.24%71 Cyclically Adjusted PB Ratio is 95.56 as of Aug. 15, 2026, which is 26% above its 10-year median of 75.78. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 716 Drug Manufacturers companies, Xeris Biopharma Holdings ranks worse than 99.44% on this metric.
The historical rank and industry rank for Xeris Biopharma Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:
XERS'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 60 Med: 75.78 Max: 98
Current: 98
During the past 10 years, Xeris Biopharma Holdings's highest Cyclically Adjusted PB Ratio was 98.00. The lowest was 60.00. And the median was 75.78.
XERS's Cyclically Adjusted PB Ratio is ranked worse than 99.44% of 716
companies
in the Drug Manufacturers industry
Industry Median: 1.76
vs XERS: 98.00
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Xeris Biopharma Holdings's adjusted book value per share data of for the fiscal year that ended in Dec25 was $0.082. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.09 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Xeris Biopharma Holdings (NAS:XERS) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Xeris Biopharma Holdings Cyclically Adjusted PB Ratio Related Terms
Xeris Biopharma Holdings Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Xeris Biopharma Holdings's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings Cyclically Adjusted PB Ratio Chart
XERS vs HROW, PRGO, PAHC: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Cyclically Adjusted PB Ratio falls into.
Xeris Biopharma Holdings Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 95.56 mean?
Xeris Biopharma Holdings (XERS) has a Cyclically Adjusted PB Ratio of 95.56 as of Aug. 15, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Xeris Biopharma Holdings and its competitors. This is 26% above median its historical median of 75.78. Over the past decade, Xeris Biopharma Holdings' Cyclically Adjusted PB Ratio has ranged from 60.00 to 98.00. According to the industry distribution chart, Xeris Biopharma Holdings ranks #712 out of 716 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Xeris Biopharma Holdings' Cyclically Adjusted PB Ratio too high?
Xeris Biopharma Holdings' current Cyclically Adjusted PB Ratio of 95.56 is 26% above median its 10-year median of 75.78. Over the past 10 years, this metric has ranged from a low of 60.00 to a high of 98.00. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.76. Xeris Biopharma Holdings' value of 95.56 is 5329.5% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #712 out of 716 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Cyclically Adjusted PB Ratio compare to HROW and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #712 out of 716 companies for Cyclically Adjusted PB Ratio. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.76. Xeris Biopharma Holdings' value of 95.56 is 5329.5% above this benchmark. Historically, Xeris Biopharma Holdings' own Cyclically Adjusted PB Ratio has ranged from 60.00 to 98.00 over the past decade. While the company's 10-year median is 75.78 vs. the industry median of 1.76, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.76, based on 716 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Cyclically Adjusted PB Ratio of 95.56 is 5329.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Cyclically Adjusted PB Ratio is 95.56, which is 26% above median its own 10-year median of 75.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $8.60 — trading 61.7% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 95.56, which is 26% above median its 10-year median of 75.78 and 5329.5% above the Drug Manufacturers industry median of 1.76. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Cyclically Adjusted PB Ratio is 95.56 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of $8.60 is trading 61.7% above its estimated GF Value™ of $5.32.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for XERS:
Cyclically Adjusted PB Ratio: 95.56 (26% above median its 10-year median of 75.78)
GF Value™: $5.32 vs. price of $8.60 (61.7% above fair value)
Industry Position: 5329.5% above the Drug Manufacturers median (#712 of 716)
No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for XERS
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XERS has been successfully added to your 
